Last reviewed 2026-05-23 · How we verify

Aplace (TROXIPIDE)

Phase 2 active Small molecule ✓ Verified May 2026

Aplace (generic name: TROXIPIDE) is a troxipide drug. It is currently in Phase 2 development for Gastric ulcer.

Troxipide works by inhibiting the enzyme H+/K+ ATPase, which is involved in stomach acid production.

Aplace is a small molecule modality. It is also known by the synonyms TROXIPIDA, TROXIPIDE, and TROXIPIDE.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	TROXIPIDE
Drug class	troxipide
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Think of it like a valve that controls the flow of acid into the stomach. Troxipide helps to close this valve, reducing the amount of acid produced and allowing the stomach to heal. This can help to treat gastric ulcers and other conditions related to excess stomach acid.

Approved indications

Gastric ulcer

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Aplace CI brief — competitive landscape report
Aplace updates RSS · CI watch RSS

Frequently asked questions about Aplace

What is Aplace?

Aplace (TROXIPIDE) is a troxipide drug, indicated for Gastric ulcer.

How does Aplace work?

Troxipide works by inhibiting the enzyme H+/K+ ATPase, which is involved in stomach acid production.

What is Aplace used for?

Aplace is indicated for Gastric ulcer.

What is the generic name of Aplace?

TROXIPIDE is the generic (nonproprietary) name of Aplace.

What drug class is Aplace in?

Aplace belongs to the troxipide class. See all troxipide drugs at /class/troxipide.

What development phase is Aplace in?

Aplace is in Phase 2.

Drug class: All troxipide drugs
Therapeutic area: All drugs in Other
Indication: Drugs for Gastric ulcer

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing